Clinical Conversations

July 11th, 2015

Podcast 179: Pradaxa (dabigatran) reversal near?

Running time: 20 minutes The anticoagulant dabigatran, marketed in the U.S. as Pradaxa, has always had the problem that, although it’s more convenient to use, there’s no sure way to stop its effect if the patient has a major bleed. Now, a monoclonal antibody fragment called idarucizumab (pronounced i-DARE-you-scis-ooh-mab) shows promise as a reversal agent. In an […]

---